Patient-oriented Research: Colon CA & Cancer Immunology

以患者为导向的研究：Colon CA

• 批准号: 7097832
• 负责人: RANDALL F HOLCOMBE
• 金额: $ 14.58万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-19 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7097832
• 关键词: cadherins; cancer prevention; colon neoplasms; combination cancer therapy; difluoromethylornithine; flow cytometry; fluorouracil; human subject; human therapy evaluation; in situ hybridization; interleukin 2; leucovorin; levamisole; microarray technology; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence; patient oriented research

DESCRIPTION (provided by applicant): This application is submitted as a competitive renewal of a midcareer investigator award in patient-oriented research (K24CA82450). The PI is Randall F. Holcombe, MD. This application details the experience, qualifications and short- and long-term patient-oriented research plans of Dr. Holcombe, as well as reviews progress during the period of support under the current award. Details about current and planned patient- oriented research is provided. These studies are focused on patient-oriented research in colon cancer and include studies related to the Wnt signaling pathway, elucidation of immunologic events in conjunction with administration of chemotherapy for colon cancer and definition of the mechanisms and potential therapeutic and cancer preventive effects of resveratrol, a naturally occuring compound found in the skin of grapes. Patients with inflammatory bowel disease, having or at high risk for colon cancer, are also studied. An additional clinical trial with laboratory correlative studies, originally designed and written by a mentee hematology-oncology fellow of Dr. Holcombe's involves the treatment of patients with gastric cancer. Mentoring activity over the past 5 years and mentoring plans for the next 5 years are described. The accomplishments of mentees are outlined as are their current activities, especially as related to ongoing participation in patient-oriented research. Ongoing mentoring plans include formal coursework, basic/translational research experiences, instruction in the development and implementation of clinical research trials, and hands-on experiences in clinical research. The original goals and objectives of the current award are reviewed and the extent to which these have been achieved is delineated. Documentation of institutional support and justification of the need for continued support through the K24 mechanism is provided.

描述（由申请人提供）：本申请是作为面向患者研究的中期研究者奖（K24CA82450）的竞争性更新提交的。PI是Randall F. Holcombe博士。该申请详细介绍了Holcombe博士的经验、资格和短期和长期的以患者为导向的研究计划，以及在当前奖项支持期间的进展情况。详细介绍当前和计划的病人为导向的研究提供。这些研究的重点是结肠癌患者导向的研究，包括与Wnt信号通路相关的研究，结肠癌化疗中免疫事件的阐明，白藜芦醇的机制和潜在的治疗和预防癌症的作用的定义，白藜芦醇是一种天然存在于葡萄皮中的化合物。患有炎症性肠病、患有或有结肠癌高风险的患者也在研究之列。另一项临床试验与实验室相关研究，最初由Holcombe博士的血液学肿瘤学学员设计和撰写，涉及胃癌患者的治疗。描述了过去5年的指导活动和未来5年的指导计划。学员的成就和他们目前的活动，特别是与正在参与的以患者为导向的研究有关的活动都被概述。正在进行的指导计划包括正式课程、基础/转化研究经验、临床研究试验开发和实施方面的指导以及临床研究的实践经验。审查了当前奖项的最初目标和目的，并描述了实现这些目标的程度。提供了机构支持的文件，以及需要通过K24机制继续支持的理由。